Zeta BCL-6 Antibody. Zeta’s recombinant rabbit antibody recognizes BCL-6, a proto-oncogenic transcription factor that is involved in regulating B cell response to DNA damage and is a marker of germinal center differentiation. BCL-6 is responsible for transcriptional regulation and lineage differentiation of follicular helper T cells. BCL-6 is a protein of 95kDa.
Zeta’s BCL-6 antibody is useful in a number of diagnostic settings: (1) differential diagnosis of small B-cell lymphoma given that follicular lymphoma will show BCL-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative; (2) BCL-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, BCL-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes; and (3) BCL-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are BCL-6 negative whereas the large (“L&H”) cells of NLPHL are BCL-6 positive. In contrast, the BCL-6 antibody rarely stains mantle-cell lymphoma and MALT lymphoma.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.